A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Avelumab (Primary) ; Trilaciclib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms PRESERVE3
- Sponsors G1 Therapeutics
- 21 Mar 2024 Status changed from active, no longer recruiting to discontinued. Sponsor no longer pursuing trial for the indication.
- 12 Jan 2024 This trial has been discontinued in Spain (Global end date: 30 Nov 2023)
- 29 Dec 2023 This trial has been discontinued in France (Global end date: 30 Nov 2023)